{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.2","upperLimit":"11.3","value":"9.7"},{"groupId":"OG001","lowerLimit":"6.5","upperLimit":"15.1","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on blinded independent central review (BICR) and investigator assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set includes all subjects for whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"9 months after the last participant is randomized or later to data cut off, up to approximately 35 months","title":"Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer","type":"SECONDARY","unitOfMeasure":"months"}